Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Age-related Macular Degeneration (AMD) Clinical Trial

Official title: Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Status Completed

Clinical Trial Summary

This study was a retrospective cohort study of patients to assess the early insights into real-world safety among wet AMD patients initiating brolucizumab. Evidence was generated to describe their patient characteristics and clinical outcomes. The study was conducted using the IRIS Registry.

Clinical Trial Description

IRIS Registry EHR data from patients with wet AMD who initiated brolucizumab were analyzed in this study.

Identification period of the index date (index period): The patients fulfilling the selection criteria was identified

• Index date: Defined as the date of the earliest brolucizumab injection

• Study Period: The period from the first patient eye exposure to brolucizumab to the last follow-up recorded

• Pre-index period: The period 36 months prior to the index date. Data within 36 months prior to the index date will be used to assess baseline characteristics.

• Post-index period: The period 180 days after the index date ;

Related Conditions & MeSH terms

• Age-related Macular Degeneration (AMD)
• Macular Degeneration

• NCT number: NCT05082415
• Study type: Observational
• Source: Novartis
• Status: Completed
• Start date: June 3, 2020
• Completion date: December 15, 2020